
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists play a key role in type 2 diabetes care by helping the pancreas release more insulin and by reducing glucose output from the liver. They are frequently prescribed when oral medicines like metformin no longer provide adequate control over fasting and post meal blood sugar levels. Some GLP-1 agents have also demonstrated cardiovascular benefits, lowering the risk of heart related complications in patients with type 2 diabetes and existing heart disease.
For adults without diabetes, GLP-1 based medications such as Wegovy and Saxenda have received FDA approval specifically for chronic weight management. By strengthening signals of fullness and reducing hunger and cravings, these drugs allow individuals to comfortably eat less without feeling constantly deprived. Research has consistently shown that combining GLP-1 therapy with healthy lifestyle habits leads to significant and durable weight loss for many people.
GLP-1 receptor agonists control blood sugar by boosting insulin secretion in response to eating and by reducing the amount of glucagon the body produces. Together, these actions limit sudden rises in blood glucose and contribute to more consistent glycemic management over time. Since their effect depends on how high blood sugar is, they carry a significantly lower risk of hypoglycemia compared with many traditional diabetes drugs.
GLP-1 therapy is especially valuable because it supports long term weight reduction rather than just short bursts of weight loss. By slowing gastric emptying and working on appetite centers in the brain to enhance satiety, these medications help lower hunger and make it easier to maintain a lower calorie intake. Studies consistently show that treatments like liraglutide, semaglutide, and tirzepatide can lead to significant, sustained weight loss when patients also follow supportive lifestyle changes.



GLP-1/GIP co-agonists target both GLP-1 and GIP receptors, improving insulin secretion and appetite regulation with greater efficiency than GLP-1 alone. These medications offer a stronger solution for managing blood glucose and hunger, making them an effective option for diabetes and weight management.
GLP-1/glucagon co-agonists interact with both GLP-1 and glucagon receptors, enhancing weight loss and energy metabolism while preserving lean muscle mass, which is essential for overall metabolic function.

